The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability
The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability. A Randomised, Blinded, Healthy Volunteer Study
The aim is to investigate the effect of perineural administration of a series of different volumes of local anaesthesia (ropivacaine 0.2%) on nerve block duration and the variability of the duration in the common peroneal nerve and the sciatic nerve in healthy volunteers.
The hypothesis is that nerve block duration is correlated to local anaesthetic volume, but only to a certain degree. After a sufficient volume a 'saturation level' will be reached, and nerve block duration will not increase further.
調査の概要
詳細な説明
The trial is divided into two similar phases. Each phase will focus on a specific nerve. Phase 1 will focus on the common peroneal nerve and Phase 2 will focus on the sciatic nerve.
After baseline measurements, the investigators will insert a peripheral intravenous catheter. Then, the investigators will insert a suture-method peripheral nerve catheter (Certa CatheterTM). Procedures will be done in a sterile manner as a standard of practice. The investigators will use an ultrasound (US)-guided short-axis, needle in-plane technique. For the US-scan, the investigators will use a linear or a curvilinear transducer.
During interventions, volunteers will be monitored with continuous pulse oximetry. Placement of the peripheral nerve catheter will be facilitated by US using small injections of mepivacaine (carbocaine 2 %) in the skin and surrounding tissues and only isotonic saline (5 mL) in the perineural space to prevent blocking of the nerve before ropivacaine injection. The catheter orifice will be placed by pulling either end of the catheter and guided by the built-in echogenic markings seen on US. Before injection of ropivacaine, the investigators will do careful aspirations through the catheter in order to prevent intravasal injection.
Each ropivacaine injection will be administered via an infusion pump. This will ensure a constant infusion rate set to 10 mL per minute. During infusion, the volunteers will be monitored with continuous pulse oximetry.
Before instigation of the ropivacaine infusion, the investigators will use US to verify full absorption of the isotonic saline in the perineural space.
For each nerve, the subject will be randomly allocated to and receive one of five possible ropivacaine volumes. All volunteers and outcome assessors will be blinded to the ropivacaine administrations and infusion procedures. Outcome assessors will not be in the room, when the medication is prepared nor given. Preparation will take place behind a curtain and therefore also blinded to the volunteers.
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Hillerød、デンマーク、DK-3400
- Claus Behrend Christiansen
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria
- Male or female 18-64 years
- American Society of Anesthesiologists Classification ≤ II
Exclusion criteria
- Body Mass Index ≤ 18 or ≥ 30
- Former surgery to the lower extremities
- Peripheral nerve disease
- Allergy to ropivacaine
- Pregnancy or breastfeeding
- Enrolment in other investigational drug studies or recent clinical trials that may interfere with this study
- Habitual use of any kind of analgesic treatment
- Anatomic abnormalities preventing successful US-guided peripheral nerve catheter insertion
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Peroneal nerve: Ropivacaine 0.2%, 2.5 mL
Perineural injection of ropivacaine 0.2 %, 2,5 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Peroneal nerve: Ropivacaine 0.2%, 5 mL
Perineural injection of ropivacaine 0.2 %, 5 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Peroneal nerve: Ropivacaine 0.2%, 10 mL
Perineural injection of ropivacaine 0.2 %, 10 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Peroneal nerve: Ropivacaine 0.2%, 15 mL
Perineural injection of ropivacaine 0.2 %, 15 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Peroneal nerve: Ropivacaine 0.2%, 20 mL
Perineural injection of ropivacaine 0.2 %, 20 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Sciatic nerve: Ropivacaine 0.2%, 5 mL
Perineural injection of ropivacaine 0.2 %, 5 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Sciatic nerve: Ropivacaine 0.2%, 10 mL
Perineural injection of ropivacaine 0.2 %, 10 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Sciatic nerve: Ropivacaine 0.2%, 15 mL
Perineural injection of ropivacaine 0.2 %, 15 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Sciatic nerve: Ropivacaine 0.2%, 20 mL
Perineural injection of ropivacaine 0.2 %, 20 mL
|
Perineural injection.
|
|
アクティブコンパレータ：Sciatic nerve: Ropivacaine 0.2%, 30 mL
Perineural injection of ropivacaine 0.2 %, 30 mL
|
Perineural injection.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of sensory nerve block
時間枠：1-24 hours
|
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve.
Testing will start after onset of sensory nerve block and continue until normal sensation has returned.
When testing the sciatic nerve, we will continue testing until normal sensation has returned in both components of the nerve, i.e. the tibial and common peroneal nerve.
|
1-24 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Length of nerve exposed to local anaesthesia
時間枠：10 minutes
|
We will measure local anaesthetic spread in a proximal-to-distal manner parallel to the nerve trajectory.
Total length of the neural spread will be reported in millimetres from the most proximal point to the most distal point in which fluid, i.e. ropivacaine, is seen on ultrasound in proximity to the nerve.
Testing will be done immediately after end of ropivacaine infusion.
|
10 minutes
|
|
Onset of sensory nerve block
時間枠：10-180 minutes
|
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve.
Testing will start ten minutes after end of infusion and continue for every fifth minute until onset.
We will test for a maximum of 180 minutes.
|
10-180 minutes
|
|
Onset of motor nerve block
時間枠：10-180 minutes
|
Testing will start ten minutes after end of infusion and continue for every fifth minute until onset.
When onset of sensory nerve block is confirmed, testing of motor nerve block onset will end as well, if not already found.
Motor nerve block of the tibial nerve will be evaluated by plantarflexion of the ankle.
Motor nerve block of the common peroneal nerve will be tested by dorsiflexion of the ankle.
|
10-180 minutes
|
|
Degree of sensory nerve block
時間枠：1-24 hours
|
We will test sensory nerve block using a subjective rating scale.
We will grade from one to four: 1) "not different from ipsilateral antebrachium"; 2) "different from ipsilateral antebrachium"; 3) "warm sensation"; 4) "no sensation".
Grades 2-4 will be considered as successful sensory nerve blocks.
It will be noted if the volunteer is in doubt.
Nevertheless, this will be considered as a successful sensory nerve block and graded as 2) in the post hoc statistical analyses.
|
1-24 hours
|
|
Degree of motor nerve block
時間枠：1-24 hours
|
This will be tested with the volunteer in the upright position using a sturdy counter for balance if necessary.
Motor strength will be evaluated using a normal everyday activation of the lower leg: A toe and a heel raise, testing the common peroneal nerve via activation of the anterior tibial muscle and the tibial nerve via activation of the gastrocnemius muscle, respectively.
Motor nerve block intensity will be evaluated on a scale from one to three: 1) normal strength, 2) paresis or 3) paralysis.
Volunteers will be asked to perform a maximum contraction building up muscle force over three seconds.
It will be noted if the volunteer is in doubt, which will be considered as 2) paresis in the post hoc statistical analyses.
|
1-24 hours
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター：Kai Henrik Wiborg Lange, MD DMSC、Nordsjællands Hospital Hillerød
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
術後の痛みの臨床試験
-
Bingol UniversityAtaturk Universityまだ募集していません術前不安 | 恐れ | PAİN
-
Dexa Medica Group完了
Ropivacaineの臨床試験
-
Poznan University of Medical Sciences募集
-
Poznan University of Medical Sciences募集
-
Institut CurieAstraZeneca; Gustave Roussy, Cancer Campus, Grand Paris完了
-
University of Malayaまだ募集していません
-
Gangnam Severance Hospital募集